IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis
Lu, J.1; Lu, J.2; Chen, W.3; Huo, Y.4; Huang, X.1; Hou, J.2; Chinese Med Doctor Assoc Hematolog
刊名BLOOD CANCER JOURNAL
2014-08-01
DOI10.1038/bcj.2014.55
4
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]RETROSPECTIVE ANALYSIS ; RACIAL DISPARITIES ; SURVIVAL ; THALIDOMIDE ; THERAPY ; IMPACT
英文摘要

The aim of this study was to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). This retrospective study enrolled 940 newly diagnosed inpatients (median age, 59 years; immunoglobulin (Ig) D isotype, 6.5%) with complete follow-up data at three centers. In all, 85.8% of patients were of Durie-Salmon stage III and 48.3% were of International Staging System (ISS) stage III at diagnosis. Also, 9.6% of patients had extramedullary plasmacytoma. Compared with IgG, IgD type patients were diagnosed at a younger age, and more patients were of ISS stage III, with hypercalcemia, elevated levels of lactate dehydrogenase, hyperuricemia, renal dysfunction and 1q21 amplification (P = 0.03). The overall survival (OS) benefit was more prominent in IgG than in IgD when patients received bortezomib; however, they showed no significant difference when they received older therapies such as melphalan combined with prednisone or vincristine combined with adriamycin and dexamethasone. Fluorescence in situ hybridization (FISH) results showed that 17.6% had 17p13 deletion. Conventional cytogenetics revealed that 13.3% were hypodiploid and those cases had the worst survival, but hyperdiploid cases (9.3%) did not show any survival benefit compared with those with a normal karyotype (77.4%). Median OS and progression-free survival for all patients were 54 and 26 months, respectively. Significant factors for survival by multivariate analysis were gender, ISS stage, number of FISH abnormalities and extramedullary disease. MM in mainland China presents with different features, with patients being of younger age and having higher risk and more survival benefit in IgG patients receiving bortezomib.

语种英语
WOS记录号WOS:000341925600009
项目编号81372535
资助机构Celgene Pharmaceutical (ShangHai) Co. Ltd ; National Natural Science Fund of China
引用统计
被引频次:13[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56749
专题北京大学第二临床医学院_血液科
作者单位1.Beijing Univ, Clin Res Inst, Beijing, Peoples R China
2.Beijing Univ, Peoples Hosp, Dept Hematol, Beijing 100044, Peoples R China
3.Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China
4.Capital Med Univ, Beijing Chaoyang Hosp, Dept Hematol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Lu, J.,Lu, J.,Chen, W.,et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis[J]. BLOOD CANCER JOURNAL,2014,4.
APA Lu, J..,Lu, J..,Chen, W..,Huo, Y..,Huang, X..,...&Chinese Med Doctor Assoc Hematolog.(2014).Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.BLOOD CANCER JOURNAL,4.
MLA Lu, J.,et al."Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis".BLOOD CANCER JOURNAL 4(2014).
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Clinical features an(730KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lu, J.]的文章
[Lu, J.]的文章
[Chen, W.]的文章
百度学术
百度学术中相似的文章
[Lu, J.]的文章
[Lu, J.]的文章
[Chen, W.]的文章
必应学术
必应学术中相似的文章
[Lu, J.]的文章
[Lu, J.]的文章
[Chen, W.]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma_ results of a multicenter analysis.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。